Segmentectomy for Solid-dominant Lung Cancer
Segmentectomy for Solid-dominant GGO-featured Invasive Lung Cancer With Size of 2-3cm: a Single-arm, Multi-center, Phase III Trial
Fudan University
277 participants
Jul 1, 2024
INTERVENTIONAL
Conditions
Summary
This is a clinical trial from Eastern Cooperative Thoracic Oncology Project (ECTOP), numbered as ECTOP-1025. The goal of this clinical trial is to confirm the theraputic effect of segmentectomy for solid-dominant invasive lung cancer with size of 2-3cm. The main questions it aims to answer are: * The 5-year disease-free survival of patients having solid-dominant invasive lung cancer with size of 2-3cm; * The post-operative lung function tests after receiving segmentectomy. Participants will receive segmentectomy as the surgical procedure.
Eligibility
Inclusion Criteria10
- Patients who sign the informed consent form and are willing to complete the study according to the plan;
- Aged from 18 to 80 years old;
- ECOG equals 0 or 1;
- Not receiving lung cancer surgery before;
- Confirmed to be invasive lung adenocarcinoma intraoperatively or postoperatively;
- Ground glass-dominant lung nodules
- Consolidation-to-tumor ratio (CTR) ranges from 0.5 to 1, and tumor size ranges from 2 to 3cm;
- cN0 without distant metastasis;
- Tumors could be completely resected assed by surgeons;
- Not receiving chemotherapy or radiotherapy before.
Exclusion Criteria5
- CTR is not 0.5-1, or size is not 2-3cm;
- Tumors could not be completely resected assed by surgeons;
- Not lung adenocarcinoma diagnosed cytologically or pathologically;
- Receiving lung cancer surgery before;
- Receiving radiotherapy or chemotherapy.
Interventions
The lungs are divided into multiple lobes. A segmentectomy involves the removal of part of one of the lobes of the lung to entirely remove a cancerous tumor. segmentectomy can preserve more normal functional lung tissues.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06634966